A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,233,970actual
Sites
1
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-21 | actual | When the study began enrolling |
| Primary completion | 2025-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
Intervention
- Other: No treatment given
Primary outcome
what the primary-completion date above is the date OFThe proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
measured January 1st, 2023, to December 31st, 2023
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed